The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | IVAC +/- rituximab in R/R B-NHLs: a real-world data review
David Straus, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses a study aiming to evaluate IVAC (ifosfamide, etoposide, and cytarabine) treatment with or without rituximab (R) in relapsed/refractory (R/R) B-cell non-Hodgkin lymphomas (NHL). The objective response rate (ORR) among evaluable patients was 48%, with 17% achieving a complete response. While ORR did not vary significantly between the IVAC+R and IVAC-R groups, it was associated with number of IVAC cycles. Patients who received R with every cycle and received 3 or more cycles all experienced significantly longer progression-free survival (PFS) and overall survival (OS), with those who underwent subsequent HCT or CAR-T therapy achieving particularly impressive OS rates. Most participants experienced serious adverse events and 19% of documented patient deaths were attributed to treatment-related complications. While these findings suggest that IVAC+R may be a useful bridging therapy for patients planning HCT or CAR-T cell therapy, its safety profile leaves room for improvement. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
